Germany's health regulator approved Exilby, a cannabis-derived medicine, as the world’s first cannabis-based painkiller for chronic pain this month [1].

The approval is significant because it introduces a pharmaceutical-grade, non-opioid treatment option for patients who struggle with chronic pain and the risks associated with powerful opioid drugs [2].

The Federal Institute for Drugs and Medical Devices (BfArM) granted the authorization in June 2026 [1]. Developed by pharma entrepreneur Clemens Fischer through the company Vertanical, Exilby aims to provide a standardized medical alternative to traditional pain management [1].

“We are thrilled to bring Exilby to patients in Germany and to pave the way for a new class of pain therapeutics,” Fischer said [1].

Health officials believe the medication could impact the lives of millions of chronic-pain patients [2]. By providing a regulated alternative, the drug may help reduce the systemic reliance on opioids, which are often linked to addiction, and overdose.

“This approval marks a significant step towards alternative pain management and offers hope to millions suffering from chronic pain,” Dr. Anna Müller, head of BfArM, said [1].

Medical practitioners suggest the move could have broader implications for public health. Dr. Michael Stein, a pain specialist, said patients will finally have a non-opioid option that could curb the opioid crisis [2].

The decision by German regulators follows a period of development focused on creating a consistent, medical-grade derivative of cannabis that can be prescribed and monitored within a clinical framework [1].

““We are thrilled to bring Exilby to patients in Germany and to pave the way for a new class of pain therapeutics.””

The authorization of Exilby represents a shift in the pharmaceutical approach to cannabis, moving it from a widely unregulated or anecdotal treatment to a formal, regulator-approved therapeutic class. If successful in Germany, this creates a regulatory precedent that other nations may follow to address the opioid epidemic through cannabis-derived alternatives.